HighTide Therapeutics Presents Analyses of a Phase 2 T2DM Study at the ADA Scientific Sessions, Highlighting Glycemic and Cardiometabolic Benefits of Berberine Ursodeoxycholate (HTD1801)

ROCKVILLE, MD and SHENZHEN, CHINA, June 21, 2024 – (ACN Newswire via SeaPRwire.com) – HighTide Therapeutics, Inc. (2511.HK), a clinical stage biopharmaceutical company specializing in the development of multi-targeted therapies for chronic liver and metabolic diseases, announced today that it will

More

Social Media Tourism Is Damaging the Planet

Fifteen years ago, a remote stretch of Icelandic countryside along the southern coast was practically deserted. The family that had owned and farmed the land for generations had relocated to Reykjavík, a three-and-a-half-hour drive away. A few adventurous visitors occasionally

More